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A major difference between binding and fusion assays commonly used to study the human immunodeficiency virus (HIV) envelope is the use
of monomeric envelope for the former assay and oligomeric envelope for the latter. Due to discrepancies in their readouts for some mutants,
envelope regions involved in CCR5 coreceptor usage were systematically studied to determine whether the discordance is due to inherent
differences between the two assays or whether it genuinely reflects functional differences at each entry step. By adding the binding inhibitor TAK-
779 to delay coreceptor binding kinetics in the fusion assay, the readouts were found comparable between the assays for the mutants analysed in
this study. Our finding indicates that monomeric binding reflects oligomeric envelope–CCR5 interaction, thus discordant results between binding
and fusion assays do not necessarily indicate differences in coreceptor usage by oligomeric envelope and monomeric gp120.
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Human immunodeficiency virus type 1 (HIV-1) infection of
host cells generally involves binding of the viral envelope to the
CD4 receptor, followed by binding to a chemokine coreceptor,
usually CCR5 or CXCR4. While receptor binding does not have
a strict temperature requirement (Doranz et al., 1999; Mkrtchyan
et al., 2005), the fusion processes proceed only at temperatures
above 25 °C (Frey et al., 1995; Melikyan et al., 2000). By
overcoming a high energy barrier, conformational changes
induced by binding result in the insertion of the fusion peptide
into the host cell membrane. Subsequent formation of the highly
stable six-helix bundle (Lu et al., 1995;Weissenhorn et al., 1996)
is associated with pore formation and membrane fusion, an
irreversible process that allows viral entry into the cell.
Although it has been thought that membrane fusion, being a
downstream process from coreceptor binding, ought to be a
function of binding capacity, various studies have reported
discrepancies in binding versus fusion data when studying
envelopes with single mutations in sites identified to be relevant⁎ Corresponding author. Fax: +1 617 739 8348.
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doi:10.1016/j.virol.2007.09.009to coreceptor binding (Hu et al., 2005, 2000; Reeves et al., 2004;
Suphaphiphat et al., 2007).
A study by Baik et al. (1999) examining usage of various
CCR5 chemokine coreceptor chimeras by JRFL envelope-
pseudotyped viruses found that the chimeras permissive for
fusion still had generally undetectable binding with the
pseudotyped viruses. Single mutations in the envelope at
residues P311 (Hu et al., 2000) and D324 (Hu et al., 2005) in the
third variable region (V3), and P438 in the fourth conserved
region (C4) (Reeves et al., 2004) have been identified to display
discordant binding and fusion characteristics.
Those studies were conducted with HIV-1 JRFL and primary
isolates (Hu et al., 2005, 2000) or YU-2 (Reeves et al., 2004),
demonstrating that this disconnect between coreceptor binding
and fusion capacities is not isolate-specific, and can be seen in
naturally occurring variants as well.
Through studies utilising an HXB2-JRFL mutant panel,
Suphaphiphat et al. (2007) identified two sets of mutants with
discordant binding and fusion levels. One group was composed
mainly of those with mutations throughout the V3 and among
bridging sheet residues in the C4 that bound CCR5 poorly
but mediated wild-type or near-wild-type levels of fusion. The
second group, distributed across the V3, was characterised by
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However, there are fundamental differences in the assays used
to study coreceptor binding and fusion that complicate the side-
by-side comparison of data.
To study direct binding to receptors involved in cell entry,
soluble monomeric envelope glycoprotein gp120 is generated
by transfection of envelope expression constructs. Harvested
soluble gp120 (sgp120) is then complexed to soluble CD4 and
the resultant complex analysed for its capacity to bind to its
respective coreceptor. In contrast, the cell–cell fusion assay
involves oligomeric envelope on a cell surface, using effector
cells transfected with constructs encoding the complete
envelope to mediate fusion with target cells expressing the
necessary receptors. While the cell–cell fusion assay reflects the
effects of envelope-receptor binding affinity on downstream
fusion (Reeves et al., 2002, 2004), the readout is expected to be
modulated by fusion kinetics. Due to these inherent differences
between the two assays, it is not possible to conclude that
discordant results demonstrate functional differences of the
gp120 mutants, rather than reflecting assay sensitivities or arti-
facts of the systems themselves. In an attempt to resolve this
issue, we explored the possibility of studying binding in the
context of the fusion assay, which would allow us to investigate
coreceptor binding with a physiologically more relevant form of
gp120. To accomplish this, the fusion assay was modified to
delay binding kinetics.
Inhibitors targeting various steps of the viral entry pathway
are commonly used to dissect the properties of each step. The
addition of TAK-779, a competitive inhibitor that binds to a
small pocket formed by the CCR5 transmembrane helices (Baba
et al., 1999), to the fusion assay reduces the gp120–CCR5
complex formation rate by lowering the concentration of free
CCR5, and has also been demonstrated to prolong the pre-fusion
lag phase associated with CD4 and coreceptor binding (Platt
et al., 2005). This decreased gp120–CCR5 complex concentra-
tion is not expected to result in significant changes in the fusion
rate, however, as this was not observed with decreased envelope
(Lineberger et al., 2002) nor decreased coreceptor expression
levels in conditions where CCR5 is not overexpressed (Reeves
et al., 2002). By delaying the coreceptor binding rate but mini-
mally affecting the fusion rate, the addition of TAK-779 to the
cell–cell fusion assay should therefore allow us to studyFig. 1. Soluble gp120–CCR5 binding and cell–cell fusion by HXB2-JRFLV3 and C4
values are expressed as a percentage of wild-type HXB2-JRFL levels. Grey bars ind
binding at less than 50%. Black bars indicate mutants with fusion over 50% that ofenvelope binding properties in the context of oligomeric,
membrane-expressed envelope and enable comparison with
the large body of fusion data available.
Results
Discordance exists between the capacity of mutants to mediate
binding versus fusion
Studies looking at the ability of coreceptor binding mutants
to enter host cells have noted that poor binding capacity does
not necessarily translate into poor fusion. In order to explore the
basis for the observed differences between binding and fusion
readouts, we based our study on the HXB2 chimera containing
the subtype B, CCR5-utilising JRFL envelope—a well-studied
molecular clone with a large volume of previous work on its
entry into the host cell. The construction and characterisation of
the HXB2-JRFL V3 and bridging sheet mutant panel used in
this study have been previously described, and envelope pro-
cessing and expression were found to be comparable to that of
the HXB2-JRFL wild-type (WT) (Suphaphiphat et al., 2007).
This mutant panel was analysed using both sgp120–CCR5
binding and cell–cell fusion assays, and the 50% cut-off value
was chosen to facilitate comparisons with previously published
work in the field.
Mutations in the V3 (positions 297–329) and select C4
bridging sheet (420–422, 438, 441) residues had little effect on
fusion levels overall (Fig. 1). Fusion of these envmutants tended
to be fairly robust, with only three residues in the V3 (R298A,
N301A, I307A) exhibiting less than 50% fusion compared to
WT and two residues in the C4 region (I420A, Q422A) at
approximately 50%. In contrast, I420A was previously de-
scribed to adversely affect CD4 binding (Suphaphiphat et al.,
2003, 2007). On the other hand, CCR5 binding was heavily
disrupted, with 22 of 38 mutants exhibiting less than 50% WT
binding and another three at around 50%. We also observed five
mutants (T297A, N300A, T317A, E320A and Q327A) with
over 100% binding compared to WT.
These results confirm previous findings that mutants with
poor binding, as determined by the sgp120–CCR5 binding
assay described, are still capable of mediating WT or near-WT
levels of fusion. Likewise, there are single residues in the V3mutants. The results are an average of at least three independent experiments. All
icate mutants with binding over 50% of WT, while stippled bars are those with
WT while hatched bars indicate those with fusion at less than 50%.
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binding compared to WT, although their fusion levels are only
near-WT rather than enhanced. Our results are largely in good
agreement with those previously reported (Suphaphiphat et al.,
2007), although mutations that affect fusion most dramatically
appear to cluster primarily in the N-terminal region of the V3
stem.
The data suggest that fusion-binding discordance is not an
uncommon phenomenon. Statistical comparison of individual
mutant activity in binding versus fusion assays by the Wilcoxon
rank-sum test revealed a significant difference (pb0.05) for 26
of the 38 mutants (Table 1, column 1). Of these 26, 6 mutants
(N301A, I307A, T310A, T318A, I322A and G319A) showed
activity trends in the same direction, 2 mutants (T317A and
E320A) exhibited enhanced binding with unaffected fusion,able 1
-values in the comparison of various assays against sgp120–CCR5 binding data
haded numbers denote comparisons where the p-valueb0.05 by the Wilcoxon
nk-sum test.T
p
S
rawhile the remaining 18 mutants exhibited binding below 50% of
WT and fusion above 50% of WT.
Fusion in the presence of TAK-779 reflects monomeric gp120
binding
In order to study the effect of the mutations on binding in the
context of oligomeric envelope glycoproteins, we attempted to
analyse coreceptor binding through the fusion assay. To do this,
we studied the mutant panel by modifying the cell–cell fusion
protocol slightly with the addition of the binding inhibitor TAK-
779 at a concentration that does not completely inhibit entry;
this will be referred to as a “moderately inhibitory” concentra-
tion. While inhibitors are routinely used in excess to arrest the
entry process at specific steps for closer examination, the use of
a moderately inhibitory concentration of TAK-779 would delay
coreceptor binding kinetics without completely abolishing
binding activity in our assay system. As the cell–cell fusion
assay is a standard procedure for studying membrane fusion,
using it as a basis for modification facilitates the study of
oligomeric envelope while enabling direct cross-analysis
between binding and fusion.
The concentration of TAK-779 for the assay was fixed at
1 nM, within the linear range of the TAK-779 inhibition curve
in the context of the fusion assay, where the IC50 was ex-
perimentally determined to be 0.9 nM (data not shown). The
inhibitor was added to the fusion protocol during the cell mixing
stage. Unlike the conventional fusion assay, where most mu-
tants display near-WT levels of activity, fusion outcome was
greatly inhibited in the presence of TAK-779 across the mutant
panel when compared against the HXB2-JRFLWT, the activity
of which was arbitrarily set at 100% (Figs. 1 and 2A). The
overall profile of the mutants in the fusion+TAK-779 assay
parallels that of the sgp120–CCR5 binding assay, where the
majority of mutants (26 out of 38) exhibited less than 50% of
the WT fusion activity (Fig. 2A). The general concordance
between the readouts of the two assays was noticeable, and
linear regression analyses were performed using Stata to com-
pare the strength of correlation between the fusion assay and the
modified fusion assay against the sgp120–CCR5 binding assay.
The correlation between the sgp120–CCR5 binding assay and
the fusion+TAK-779 assay was found to have an R2 of 0.4712.
The correlation between the sgp120–CCR5 binding assay and
the standard fusion assay, however, was considerably lower
(R2 =0.2047). This suggests that the modification to the fusion
assay yields results that are more compatible with the binding
assay utilising soluble monomeric gp120 compared to the
conventional fusion assay.
It should be noted that discrepancies between the sgp120–
CCR5 binding and the fusion+TAK-779 assays still exist for
some mutants. Eleven mutants showed a significant difference
(pb0.05) when individually compared across the two assays
(Table 1, column 3). Of these, one mutant (N301A) displayed
similarly low activity and one mutant (A328G) had similarly
high activity in both assays despite the significant difference.
Four (T297A, T317A, E320A and Q327A) were designated
very high binders (with binding over 100% that of WT) via the
Fig. 2. Fusion in the presence of inhibitors. (A) Fusion levels in the presence of 1 nM TAK-779. The results are an average of at least four independent experiments, and
are illustrated alongside the sgp120–CCR5 binding data for comparison. Grey bars indicate mutants with binding over 50% of WT, while stippled bars are those with
binding at less than 50%. Black bars indicate mutants over 50% ofWT in the fusion+TAK-779 assay while hatched bars indicate those under 50%. (B) Fusion levels in
the presence of 0.5 μg/mLT-20. Hatched bars indicate less than 50%WT activity. Colorimetric readout is expressed as a percentage of wild-type HXB2-JRFL levels.
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stage did not reflect this enhanced binding with over 100%
fusion readout, even in the presence of TAK-779. The remaining
5 (P299A, K305A, I309A, R313A and H329A) mutants showed
activity trends in opposite directions.
We next investigated the effect of a non-binding inhibitor on
the fusion assay to ensure that the observed correlation was not
due to unspecific inhibitor activity. The fusion inhibitor T-20,
selected for this purpose, is a small peptide corresponding to the
first heptad repeat of gp41 (Wild et al., 1993; Kilby et al., 1998).
The T-20 IC50 against the WT HXB2-JRFL was determined to
be 0.3 μg/mL for our cell–cell fusion assay (data not shown). To
assay the effect of a moderately inhibitory concentration of T-20,
the optimised concentration of 0.5 μg/mL was used on the entire
mutant panel. As expected, regression analysis shows that
the fusion+T-20 assay displays poorer concordance with the
sgp120–CCR5 binding assay (R2 =0.1463) than the standard
fusion assay (R2 =0.5031) (Figs. 1 and 2B). Although seven
mutants (R298A, N301A, Y316A, R326A, I420A, Q422A and
G441A) exhibited less than 50% of the WT fusion level in the
fusion+T-20 assay, compared to the three mutants in the stan-
dard fusion assay, their values were not significantly different
(data not shown).
In contrast, when fusion+T-20 data were compared to the
results obtained through the gp120–CCR5 binding assay, a
significant difference of pb0.05 was seen in 26 out of 38
mutants, suggesting a strong discordance between envelopefunction as quantified by the sgp120–CCR5 binding assay and
the fusion+T-20 assay (Table 1, column 2). Regression analysis
of the two data sets reflects this discordance (R2 =0.1463).
This demonstrates that the binding-like profile seen with the
fusion+TAK-779 assay is not due to non-specific inhibitor
activity in the fusion assay context.
Differences in TAK-779 sensitivity have little effect on binding
profile
In the fusion assay, we selected a TAK-779 concentration
from the inhibition curve against the WT HXB2-JRFL with the
assumption that the single alanine mutations would not
drastically alter TAK-779 efficacy beyond the linear range of
this inhibition curve, and that the effect of TAK-779 inhibition
on each mutant would be proportional to its effect on the WT.
However, it has been shown that binding and fusion kinetics play
a role in modulating inhibitor sensitivity (Reeves et al., 2002,
2004). Therefore, with the noticeable differences in binding
capacities of the various mutants, it is possible that differences in
sensitivity to TAK-779 may render the fusion+TAK-779 assay,
with its fixed inhibitor concentration, imprecise in its analysis of
coreceptor binding.
To determine whether the alanine mutations affected the
efficacy of TAK-779 inhibition, we tested the panel against a
fixed moderately inhibitory concentration of TAK-779 via the
sgp120–CCR5 binding assay in order to compare the resulting
Fig. 3. CCR5 binding levels by the sgp120–CCR5 assay in the presence of 0.05 nM TAK-779. Colorimetric readout is expressed as a percentage of wild-type HXB2-
JRFL levels. The results are an average of at least four independent experiments, and are illustrated alongside the sgp120–CCR5 binding data for comparison. Grey
bars indicate mutants with binding over 50% of WT, while stippled bars are those with binding at less than 50%. Black bars indicate mutants over 50% that of WT in
the binding+TAK-779 assay while hatched bars indicate those under 50%.
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assay. We hypothesised that if the mutations did not result in a
noticeable change in TAK-779 efficacy, the effect of the binding
inhibitor on CCR5 binding should be proportional to the de-
creased activity seen with the WT, and therefore similar to the
panel's binding profile via the sgp120–CCR5 binding assay.
We selected a fixed concentration of TAK-779 for this assay
by generating an inhibition curve against the WT HXB2-JRFL.
Due to the low concentration of sgp120 in the supernatant, the
IC50 is about one log lower, at approximately 0.08 nM. The
TAK-779 concentration for this assay was optimised at 0.05 nM,
in the linear range of the inhibition curve (data not shown).
We found that, for almost all the mutants, the resulting profile
was not significantly different from that generated by the
sgp120–CCR5 binding assay in the absence of TAK-779 (Fig. 3
and Table 1). Despite drastic changes in the binding capacity of
many of these mutants compared toWT, the decreases in binding
activity in the presence of TAK-779 remained proportional to
that of theWT. As the binding profile is not significantly affected
by alterations in TAK-779 sensitivity, this observation further
supports our argument that the fusion+TAK-779 assay provides
a good approximation of coreceptor binding as measured by the
sgp120–CCR5 binding assay.
It was noted that five mutants (T297A, N300A, T317A,
E320A and Q327A) bound at noticeably higher levels in the
presence of the inhibitor (over 100% that ofWT). These originally
demonstrated coreceptor binding over 100% that of WT by the
sgp120–CCR5 binding assay as well. The high binding seen
through the sgp120–CCR5 binding assaymay be due to enhanced
binding kinetics, whereby the reduction in the window of
opportunity for TAK-779 activity results in a disproportionately
decreased sensitivity to TAK-779.
Discussion
The discordance observed between binding and fusion for
some HIV-1 env mutants is an unresolved question concerning
our understanding of gp120 function in viral entry. Unfortu-
nately, the interpretation of such binding and fusion data is
complicated by the technical difficulty in directly studyingcoreceptor binding with oligomeric envelope. To bridge this
gap in knowledge, we utilised the well-characterised chimera
HXB2-JRFL and its associated panel of V3 and C4 bridging
sheet mutants to analyse CCR5 coreceptor usage.
Our preliminary sgp120–CCR5 binding and cell–cell fusion
survey of the mutant panel confirms previous reports of dis-
crepancy between results obtained from the two assays. There
are a few differences between the fusion results reported here
compared to a previous study (Suphaphiphat et al., 2007), which
reported residues in the C-terminal V3 stem exhibiting over 50%
fusion; this difference may be attributed to modifications to the
fusion assay used. Also, the same study reported some HXB2-
JRFL V3 mutants with exceptionally high binding (N300A,
A314G, T317A, E320A, Q327A). While we did not see the
same magnitude of enhanced binding in this study, we did
observe binding over 100% that of WT and the effect of these
mutations on binding kinetics becomes apparent in the presence
of TAK-779. Our findings also confirm previous reports where
V3 mutants P311A and D324A, and C4 mutant P438A were
characterised as poor binders capable of mediating fusion and
infection at levels that did not differ significantly from WT (Hu
et al., 2005, 2000; Reeves et al., 2004).
One of the unanswered questions concerning the discordant
binding and fusion data is whether or not they reflect differences
in native envelope function at these two entry steps, due to the
assaying of binding with monomeric gp120 and fusion with
oligomeric envelope. From our experiments, however, we have
observed that the fusion+TAK-779 assay readout reflects that of
the sgp120–CCR5 binding assay more so than the standard
fusion assay, despite the different assay setups and, most im-
portantly, the use of cell-surface expressed oligomeric envelope.
The fusion+TAK-779 assay was able to predict coreceptor
binding trends (based on the 50% WT activity cut-off) via the
sgp120–CCR5 assay for 87% (33 of 38) of themutants analysed,
with the remaining five mutants exhibiting different activity
trends in opposite directions. This contrasts with the standard
fusion assay, where directional concordance with the sgp120–
CCR5 binding assay is only 51% (20 of 38 mutants). Con-
sidering that an assay utilising soluble and monomeric gp120
has a predictive value of 87% for an assay based on oligomeric
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gp120 are not necessarily fundamentally different in their
coreceptor use. Furthermore, these results support the relevance
of binding data generated by the use of sgp120.
Another explanation offered for the observed differences in
binding and fusion capacity is the possibility that reduction in a
monomer's binding affinity can be compensated for by the
multiple contacts available in the envelope's oligomeric form,
which grant a higher overall binding avidity in a synergistic
manner. While our study was not designed to definitively re-
solve this issue, we show here that this is not necessarily the
case. The oligomeric envelope still displays similar deficiencies
in binding, as scored by the fusion+TAK-779 assay, among
those mutants identified as poor binders by the sgp120–CCR5
binding assay, despite having multiple contacts. These results
suggest that each individual monomeric gp120 unit contains
sufficient conformational determinants of coreceptor binding.
Previous CCR5 studies have dissected the V3 into domains
with distinct functions (Doranz et al., 1997; Hu et al., 2000;
Cormier and Dragic, 2002; Cormier et al., 2001). Our findings
offer an additional perspective on coreceptor usage, looking at
distinct involvement of the V3 in monomeric versus oligomeric
envelope. We find binding to be primarily a function of mono-
meric contacts, and the oligomeric form of the envelope com-
pensates for low binding affinity to allow for WT or near-WT
levels of fusion via determinants distinct from those involved in
coreceptor binding. Indeed, it has been noted that V3 loop
mutations may alter the kinetics by which conformational
change occurs upon coreceptor binding (Platt et al., 2005). This
post-binding effect, distinct from the determinants of binding
kinetics, may account for differences in the capacity of the
envelope to mediate coreceptor binding and fusion.
While our data suggest that these monomeric and oligomeric
forms are functionally similar, it is possible that the increased
number of contacts in the oligomeric form still provides an
additive effect on binding, proportional to the binding profile of
monomeric gp120, even if the multiple oligomeric envelope
contacts do not appear to synergistically enhance binding affinity.
As we normalise the measurements by considering the wild-type
values as 100%, the assays are not designed to directly compare
the magnitudes of binding mediated by soluble gp120 with that
of native envelope, and we cannot conclusively state that
oligomeric envelope binds at the same magnitude as monomeric
envelope.
Along with this limitation of our assay systems, we also note
that not all mutants showed a strong correlation between mono-
meric and oligomeric binding as measured by the sgp120–
CCR5 and fusion+TAK-779 assays. For instance, T297A and
Q320Awere found to mediate very high binding, at over 100%
that of WT when assayed with the sgp120–CCR5 assay. Yet,
when binding was studied in the context of oligomeric envelope,
the fusion readout was less than that of WT. This suggests that
the use of TAK-779 as amodification to the fusion assaymay not
accurately reflect the extent of oligomeric binding in cases where
the soluble form of the envelope is capable of mediating very
high binding. It is possible that the soluble form of these mutants
may have greater exposure of coreceptor binding sites or morereadily undergo conformational changes associated with re-
ceptor binding, and that these binding advantages are not present
in the oligomeric form, which may block such exposure or
hinder conformational change. Factors determining coreceptor
binding and fusion may be independent to a certain degree, and
the energetically demanding process of fusion peptide formation
heavily modulates the readout of the fusion+TAK-779 in these
cases.
On the other end of the binding spectrum, it was observed that
a large number of mutants exhibited low binding activity.
Although it has been shown that envelopes with reduced binding
are more sensitive to inhibition (Reeves et al., 2002, 2004), we
noted that, amongmutants with defects in binding, their capacity
to bind to CCR5 in the presence of TAK-779 was not signifi-
cantly different from sgp120–CCR5 binding, when expressed as
a percentage of WT activity. These results do not necessarily
contradict the possibility that poor binders are more sensitive to
TAK-779 inhibition due to slower binding kinetics. Due to the
small magnitude of the measurements for these mutants, the
sgp120–CCR5 binding assay does not appear to be ideal for
detecting the proportionally small increase in sensitivity to the
inhibitor, when compared to the greater resolution provided by
IC50 determinations. Nevertheless, this limitation in sensitivity
can be valuable, as decreased binding kinetics and subsequent
increases to inhibitor sensitivity would not significantly affect
the predictive value of the fusion+TAK-779 assay.
While previous studies have noted only the occasional dis-
cordance between binding and fusion outcomes as an unexpect-
ed characteristic of envelope mutants, our systematic survey of
the V3 and selected bridging sheet residues in the C4 has re-
vealed that this is not unusual. Rather, it appears that deficiencies
in binding are generally compensated for in the downstream
stage of membrane fusion, demonstrating that such mutants may
not be disadvantaged in the process of viral entry. Furthermore,
the three mutations that strongly diminished both binding and
fusion capacity clustered in the Nt of the V3 loop, suggesting
that this region of the V3 may play a role in both stages of entry.
While it remains to be investigated whether or not these
mutations affect these two stages independently, our results and
work by Platt et al. (2001) showing V3 mutations modulating
fusogenicity rather than CCR5 affinity argue that this may be the
case.
In conclusion, these experiments utilise a simple method for
studying the binding properties of oligomeric envelope through
the modification of a standard protocol. The results demonstrate
relative concordance between oligomeric and monomeric
function, arguing that monomeric gp120 is generally function-
ally sufficient in coreceptor binding. They also help to resolve
several previously described discordances between coreceptor
binding and fusion data, demonstrating that those observations
reflect genuine differences in envelope function at these two
entry steps, and are not merely artifacts of the assay systems. Our
conclusions also validate previous studies using soluble, mono-
meric gp120, showing that these studies may contain informa-
tion that is applicable to the native HIV envelope, and that the
analyses of envelope function through the sgp120–CCR5
binding assay can be an adequate proxy for native envelope.
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binding exhibit noticeably decreased sensitivity to TAK-779
while any increased sensitivity among poor binders does not
register to any significant magnitude in binding analyses, may
have implications for the clinical application of TAK-779 and
related binding inhibitors. We speculate that viruses that acquire
mutations conferring enhanced binding capacity may exhibit a
disproportionately greater decrease in sensitivity to TAK-779,
while a gain in TAK-779 sensitivity against viral strains with
decreased binding capacity may not translate into a significantly
greater efficacy of the inhibitor against the virus.
Methods
Materials
Cell lines were obtained from the NIH AIDS Research and
Reference Reagent Program and maintained at 37 °C. Human
kidney 293 cells were cultured inDMEMsupplementedwith 10%
fetal bovine serum and 1% penicillin–streptomycin (DMEM/
FBS/PS) (Invitrogen, Carlsbad, CA). U87-CD4-CCR5 cells were
cultured in DMEM/FBS/PS with 1 μg/mL puromycin (Sigma, St.
Louis, MO) and 300 μg/mL genecitin (Roche, Indianapolis, IN).
Cf2Th/synCCR5 cells (Mirzabekov et al., 1999) were cultured in
DMEM/FCS/PS with 3 μg/mL puromycin, 500 μg/mL genecitin
and 500 μg/mL zeocin (Invitrogen, Carlsbad, CA).
The HXB2-JRFL construct, containing the envelope region
of the CCR5-using subtype B isolate JRFL in the HXB2
backbone, and the construction of its corresponding V3 and
bridging sheet mutant panel, as well as their gp120 expression
constructs, have been described previously (Suphaphiphat et al.,
2007). Recombinant vaccinia constructs vCB21R-lacZ and
vTF7-3 (Fuerst et al., 1986) were acquired through the NIH
AIDS Research and Reference Reagent Program.
Cell–cell fusion
The cell–cell fusion assay was performed as previously
described (Suphaphiphat et al., 2007), with some modifica-
tions. 8×104 293 cells were plated in 96-well tissue culture
plates for transfection with 0.5 μg of proviral DNA. After 48 h,
the cells were infected with the recombinant vaccinia vTF7-3 at
a multiplicity of infection (MOI) of 10. This construct expresses
the T7 polymerase under the control of the early/late vaccinia
promoter P7.5. An equivalent number of U87-CD4-CCR5 cells
were infected with 10 MOI of recombinant vaccinia vCB21R-
lacZ, which contains the lacZ gene under the control of the T7
promoter. The cells were washed in PBS and trypsin after 1.5 h
and left to incubate overnight. The U87-CD4-CCR5 cells were
detached by scraping, and mixed with the 293T cells in the
presence of 40 μg/mL AraC. After a 3-h incubation, the cells
were washed and lysed with Reporter Lysis Buffer (Promega,
Madison, WI) for 10 min at room temperature. Fusion was then
quantified using the β-Gal Assay Kit (Invitrogen, Carlsbad,
CA) to assay for β-galactosidase activity, according to the
manufacturer's instructions, and the absorbance was read at
405 nm.Soluble gp120–CCR5 coreceptor binding
The binding assay was performed as previously described
(Suphaphiphat et al., 2007), with some modifications. 293 cells
were transfected with HXB2-JRFL sgp120 expression vectors,
and the supernatants harvested for the binding assay. 5×104
Cf2Th-synCCR5 cells were plated in 96-well tissue culture
plates. After overnight incubation at 37 °C, they were fixed with
5% formaldehyde for 5 min, washed in PBS+0.05% Tween and
blocked with 5% milk in PBS. 0.5 μg of soluble CD4 (Protein
Sciences, Meriden, CT) was added to supernatant containing
sgp120 and incubated with mixing for 1 h at room temperature.
200 μL of the supernatant containing the sgp120-CD4 complex
was then added to each well and incubated at room temperature
for 2 h. The wells were then washed with PBS+0.05% Tween,
and 1 μg/mL of the mouse-anti-CD4 monoclonal antibody M-
T441 (Ancell, Bayport, MN) was added per well for 1 h. After
washing, a 1:5000 dilution of horseradish peroxidase-conjugat-
ed goat anti-mouse Ig monoclonal antibody (Pierce, Rockford,
IL) was added for 1 h. For colorimetric analysis, 100 μL of 1-
Step Ultra TMB ELISA (Pierce, Rockford, IL) was added to
each well, and 4 N sulphuric acid used to stop colour
development. The absorbance was read at 450 nm.
Inhibition of fusion and binding assays
TAK-779 and the T-20 fusion inhibitor from Roche were
obtained from the NIH AIDS Research and Reference Reagent
Program. In the fusion assay, 1 nM of TAK-779 was added to
each well of the 96-well plate upon mixing of 293 and U87-
CD4-CCR5 cells. In the binding assay, 0.5 nM T-20 was added
to each well upon addition of CD4-complexed sgp120 to the
fixed Cf2Th-synCCR5 cells.
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